Abstract Search

ea0026p84 | Endocrine tumours and neoplasia | ECE2011

The demethylating agent 5-aza-2-deoxycytidine upregulates somatostatin type 2 receptor expression and enhances internalization of radiolabeled somatostatin analogue in human carcinoid tumour cells

Veenstra M J , van Koetsveld P M , Farrel W E , Dogan F , Waaijers A M , Sprij-Mooij D M , Lamberts S W J , Vitale G , Hofland L

Introduction: Neuroendocrine tumors (NET) are rare tumors originating from various types of neuroendocrine cells. The somatostatin receptor type 2 (sst2) is expressed in NET cells and is a target for therapy with somatostatin analogues.Epigenetic changes including methylation of DNA at CpG dinucleotides, and particularly in the promoter region of genes can inhibit transcription. Methylation can be inhibited by cytidine analogues such as 5-aza-...

0 shares

Endocrine Abstracts

The demethylating agent 5-aza-2-deoxycytidine upregulates somatostatin type 2 receptor expression and enhances internalization of radiolabeled somatostatin analogue in human carcinoid tumour cells

BiosciAbstracts